Story · Medicine & Biotech · Mind & Brain
SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes
1 outlet · first reported by Mayo Clinic Proceedings on
To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes. (Mayo Clinic Proceedings)
Coverage, in order
-
SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes
To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.